. 2015 Sep-Oct;19(5):639–643. doi: 10.4103/2230-8210.163187
Copyright: © Indian Journal of Endocrinology and Metabolism
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Table 3.
Duration of pioglitazone use and prevalence of bladder cancer
